首页> 外文OA文献 >Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion
【2h】

Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion

机译:CHD1L在肝细胞癌中的临床意义及病毒介导的CHD1L耗竭的治疗潜能

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Hepatocellular carcinoma (HCC) is among the most lethal of human malignancies. It is difficult to detect early, has a high recurrence rate and is refractory to chemotherapies. Amplification of 1q21 is one of the most frequent genetic alterations in HCC. CHD1L is a newly identified oncogene responsible for 1q21 amplification. This study aims to investigate the role of CHD1L in predicting prognosis and chemotherapy response of patients with HCC, its chemoresistant mechanism and whether virus-mediated CHD1L silencing has therapeutic potentials for HCC treatment. Methods: The clinical significance of CHD1L in a cohort of 109 HCC cases including 50 cases who received transarterial chemoembolisation treatment was assessed by clinical correlation and Kaplan-Meier analyses. A CHD1L-overexpressing cell model was generated and the mechanism of chemoresistance involving CHD1L was investigated. An adenovirus-mediated silencing method was used to knockdown CHD1L, and its effects on tumorigenicity and chemoresistance were investigated in vivo and in vitro. Results: Overexpression of CHD1L was significantly associated with tumour microsatellite formation (p=0.045), advanced tumour stage (p=0.018), overall survival time (p=0.002), overall survival time of patients who received transarterial chemoembolisation treatment (p=0.028) and chemoresistance (p=0.020) in HCC. Interestingly, CHD1L could inhibit apoptosis induced by 5-fluorourail (5-FU) but not doxorubicin. The mechanistic study revealed that the involvement of the Nur77-mediated pathway in chemotherapeutic agent-induced apoptosis can dictate if CHD1L could confer resistance to chemotherapy. Furthermore, an adenoviral vector containing short hairpin RNAs against CHD1L (CHD1L-shRNAs) could suppress cell growth, clonogenicity and chemoresistance to 5-FU. An in vivo study found that CHD1L-shRNAs could inhibit xenograft tumour growth and increase the sensitivity of tumour cells to 5-FU in nude mice. Conclusions: This study highlighted for the first time the prognostic value of CHD1L in HCC and the potential application of virus-mediated CHD1L silencing in HCC treatment.
机译:背景:肝细胞癌(HCC)是最致命的人类恶性肿瘤之一。早期发现困难,复发率高,化学疗法难治。 1q21的扩增是肝癌中最常见的遗传变异之一。 CHD1L是新鉴定的致癌基因,负责1q21扩增。本研究旨在探讨CHD1L在预测HCC患者的预后和化疗反应中的作用,其化学耐药机制以及病毒介导的CHD1L沉默是否具有治疗HCC的潜力。方法:通过临床相关性和Kaplan-Meier分析评估CHD1L在109例HCC患者中的临床意义,其中包括50例接受经动脉化疗栓塞治疗的患者。生成了CHD1L过表达的细胞模型,并研究了涉及CHD1L的化学耐药机制。腺病毒介导的沉默方法被用来敲低CHD1L,并在体内和体外研究了其对致瘤性和化学抗性的影响。结果:CHD1L的过表达与经微动脉化疗栓塞治疗的患者的微卫星形成(p = 0.045),肿瘤晚期(p = 0.018),总生存时间(p = 0.002),总生存时间显着相关(p = 0.028) )和HCC中的化学抗药性(p = 0.020)。有趣的是,CHD1L可以抑制5-氟尿嘧啶(5-FU)诱导的凋亡,但不能抑制阿霉素。机理研究表明,Nur77介导的通路参与化学治疗剂诱导的细胞凋亡可以决定CHD1L是否可以赋予对化学疗法的抗性。此外,包含针对CHD1L的短发夹RNA(CHD1L-shRNA)的腺病毒载体可以抑制细胞生长,克隆形成和对5-FU的化学耐药性。一项体内研究发现,CHD1L-shRNA可以抑制异种移植瘤的生长,并增加裸鼠体内肿瘤细胞对5-FU的敏感性。结论:本研究首次强调了CHD1L在肝癌中的预后价值以及病毒介导的CHD1L沉默在肝癌治疗中的潜在应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号